首頁 › 骨髓增生異常症候群 › 伊利諾 › Chicago
Chicago, IL 的 骨髓增生異常症候群 臨床試驗
13 項針對 骨髓增生異常症候群 的研究正在 Chicago（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
招募中2 期
- Northwestern University, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- 還有 1 項
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
招募中2 期
- Northwestern University, Chicago
- Swedish Covenant Hospital, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
招募中1 期
- University of Chicago Comprehensive Cancer Center, Chicago
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
招募中3 期
- University of Chicago, Duchossois Center for Advanced Medicine (DCAM), Chicago
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
招募中1/2 期
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
招募中
- Northwestern University Feinberg School of Medicine, Chicago
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
招募中2 期
- University of Illinois Cancer Center, Chicago
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
招募中1/2 期
- Northwestern University, Chicago
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
招募中1/2 期
- Northwestern, Chicago
Venetoclax Basket Trial for High Risk Hematologic Malignancies
招募中1 期
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
招募中
- University of Chicago Comprehensive Cancer Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Chicago
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
招募中1 期
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
其他城市的 骨髓增生異常症候群 試驗
- Houston, TX43 項研究
- Baldwin Park, CA26 項研究
- New York City, NY21 項研究
- Seattle, WA21 項研究
- Washington, DC20 項研究
- Tampa, FL19 項研究
- Boston, MA19 項研究
- Miami, FL17 項研究
- Durham, NC14 項研究
- Columbus, OH14 項研究
- St. Louis, MO13 項研究
- Atlanta, GA13 項研究
Chicago 的其他研究
- 非小細胞肺癌61 項研究
- 乳癌59 項研究
- 癌症（所有類型）51 項研究
- 轉移性癌症45 項研究
- 前列腺癌45 項研究
- 肺癌41 項研究
- 肥胖症41 項研究
- 卵巢癌36 項研究
- 大腸直腸癌34 項研究
- 中風34 項研究
- 心臟衰竭31 項研究
- 過重29 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。